

Responses to reviewers' comments

Reviewer #1:

The editorial from Drs Shi and Yu is focused on an upcoming issue that, in my personal opinion, will raise even stronger in the next years. Recent evidence have been published of the astonishing impact of the FOLFIRINOX CT in pancreatic cancer in the neoadjuvant setting. Well this is what we missed until today. Out of any enthusiasm I am strongly convinced that the neoadjuvant strategy should be applied to any pancreatic cancer and I believe that now is the time to look forward, they are doing that. The editorial is well written, concise and complete. I recommend publication.

Answer: Thank you for your positive evaluation and professional comments.

Reviewer #2:

The authors imply that it is time to consider a strategy to select pancreatic cancer patients with liver metastatic for surgical intervention. Synchronous resection of pancreatic cancer and liver metastases may benefit some patients. There are some minor problems:

1. There need more evidence for patients who benefit from synchronous resection of primary pancreatic cancer and liver metastases.

Answer: Thank you for your concerns. We have added more citations to support our viewpoint.

2. Some sentences were repeated. The manuscript need further to be polished.

Answer: Thank you for your comments. The repeated or similar sentences have been deleted. The manuscript has been polished according to your kind suggestions.